Technology | September 18, 2012

Covidien Adds CTO Crossing and Re-Entry Catheters for Peripheral Artery Disease

Viance Crossing Catheter and Enteer Re-entry System offer new approach to chronic total occlusions in peripheral arteries

Covidien Ltd Viance Crossing Catheter Enteer Re-entry System Cath Lab Catheters

September 18, 2012—Covidien announced the launch of the Viance Crossing Catheter and Enteer Re-entry System for treating chronic total occlusions (CTOs) endovascularly. The devices are now available in the United States, the European Union (EU) and other select international markets.

“Management of the lower extremity CTO remains challenging for endovascular physicians,” said David B. Jessup, M.D., of PeaceHealth St. Joseph Medical Center in Bellingham, Wash. “Effective devices for CTO crossing and re-entry can expand the number of patients who have access to endovascular treatment of peripheral arterial disease, which may help patients avoid more invasive treatments and allow physicians to offer amputation-saving procedures.”

For effective treatment, physicians must be able to successfully cross lesions. The new tools from Covidien are designed to enable access to the distal end of a lesion, allowing physicians to treat even the most challenging lesions endovascularly. Together, the Viance Crossing Catheter and the Enteer Re-entry System offer a solution that leverages the skill and finesse of the physician rather than brute force or capital equipment.

“Covidien now offers a unique solution for the treatment of CTOs,” said Brian Verrier, vice president and general manager, peripheral vascular, Covidien. “By adding these products to our market-leading peripheral portfolio, we strive to demonstrate our commitment to advancing the treatment of vascular disease worldwide by delivering innovation that achieves both clinical and economic value for our healthcare partners.”

Competitive crossing devices rely on more aggressive cutting, grinding or pounding motions, and can be more difficult to control. Moreover, the distinctive shape of the re-entry balloon enables it to self-orient within the vessel. No other product on the market utilizes this balloon technology for a re-entry system.

The announcement was made at the 2012 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress.

For more information: www.covidien.com

Related Content

Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters | July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
Roxwood Medical, MicroCross Catheter, full U.S. launch

Image courtesy of Roxwood Medical

Technology | Catheters | January 07, 2016
Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited...
Overlay Init